Sign in

    Len Levi

    Research Analyst at Dotdot Partners

    Len Levi is a Research Analyst at Dotdot Partners specializing in therapeutic markets, with a particular focus on the evolution of NASH and Hepatitis C treatments. He is known for providing in-depth coverage of key pharmaceutical companies active in these sectors, and his analytical approach has contributed to Dotdot Partners' reputation for robust healthcare research. Levi began his career in equity research, joining Dotdot Partners after gaining experience with other leading healthcare investment firms. He holds relevant professional credentials typically required for research analysts, such as FINRA registration and securities licenses, and is recognized for insightful industry analysis that informs investor decision-making.

    Len Levi's questions to GALECTIN THERAPEUTICS (GALT) leadership

    Len Levi's questions to GALECTIN THERAPEUTICS (GALT) leadership • Q4 2016

    Question

    Len Levi of Dotdot Partners asked for perspective on the evolution of the NASH therapeutic market, drawing a parallel to Hepatitis C, and questioned at which stage of disease progression insurers and doctors would likely authorize initial treatments.

    Answer

    President and CEO Peter Traber agreed with the premise, stating that the progression from early fatty liver disease to cirrhosis can take 20 years. He emphasized that targeting patients with compensated cirrhosis, who are about five years from complications, is a more accepted approach for physicians and insurers. This is because the risk of serious outcomes is much higher and more immediate compared to early-stage NASH, where long-term morbidity is less certain and lifestyle changes can be effective, making payers more reluctant to cover decades of treatment.

    Ask Fintool Equity Research AI